Study on Trabectedin in Advanced Rearranged Mesenchymal Chondrosarcoma

This study is testing whether trabectedin (a chemotherapy drug originally derived from a sea creature) can treat a rare and aggressive bone/cartilage cancer called mesenchymal chondrosarcoma that has a specific genetic change (HEY1-NCOA2 fusion) and has progressed on prior treatment. **You may be eligible if...** - You are at least 16 years old - You have a confirmed diagnosis of mesenchymal chondrosarcoma with the HEY1-NCOA2 genetic fusion (verified by a central lab) - Your cancer is locally advanced or has spread to other organs - Your cancer has progressed in the past 6 months - You have already received at least one prior chemotherapy containing anthracyclines (up to 3 prior treatment lines) - Your blood counts and organ function are within acceptable ranges **You may NOT be eligible if...** - You have not yet received any prior chemotherapy for advanced disease - You have had more than 3 prior lines of treatment - You are pregnant or breastfeeding - You have serious organ dysfunction Talk to your doctor to see if this trial is right for you.